Scholar Rock Holding Corporation (SRRK)

13.96 -0.13 (-0.92%) At close: 04:00PM EDT

Scholar Rock Holding Corporation

301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 150

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jay Thomas Backstrom M.D., M.P.H.	President, CEO & Director	686.49k	N/A	1955
Mr. Edward H. Myles MBA	CFO, COO & Treasurer	668.49k	N/A	1972
Ms. Junlin Ho J.D.	General Counsel & Corporate Secretary	563.73k	N/A	1979
Mr. Mo Qatanani Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	N/A	N/A	N/A
Ms. Caryn Parlavecchio	Chief Human Resources Officer	N/A	N/A	1972
Ms. Lisa Amaya Price	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Erin Moore	Senior Vice President of Finance	N/A	N/A	1975
Mr. Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	N/A	N/A	N/A
Dr. Jing L. Marantz M.B.A., M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Scholar Rock Holding Corporation’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.